Vertex Pharmaceuticals
VRTX
696 hedge funds and large institutions have $46.7B invested in Vertex Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 254 increasing their positions, 247 reducing their positions, and 58 closing their positions.
22% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 58
14% more call options, than puts
Call options by funds: $403M | Put options by funds: $352M
14% more capital invested
Capital invested by funds: $41B → $46.7B (+$5.64B)
3% more repeat investments, than reductions
Existing positions increased: 254 | Existing positions reduced: 247
1% more funds holding
Funds holding: 690 → 696 (+6)
0% more funds holding in top 10
Funds holding in top 10: 16 → 16 (0)
0% more ownership
Funds ownership: 94.74% → 94.74% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$511M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$473M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$305M |
| 4 |
Jennison Associates
New York
|
+$203M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$126M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$586M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$191M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$143M |
| 4 |
Goldman Sachs
New York
|
-$133M |
| 5 |
PC
PointState Capital
New York
|
-$132M |
VRTX Hedge Fund Activity: Q3 2018 in Review
696 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2018, worth a combined $46.7B — up 14% from $41B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new VRTX positions and 58 closed out — a net gain of 13 holders — while 254 added to existing stakes and 247 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $511M. The largest seller was Capital World Investors, cutting an estimated $586M.
- 696 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2018, up from 690 in Q2 2018.
- Funds reported $46.7B of Vertex Pharmaceuticals stock for Q3 2018, up 14% quarter-over-quarter.
- 71 funds opened new Vertex Pharmaceuticals positions in Q3 2018 and 58 closed out, a net change of +13 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2018 was Capital International Investors, an estimated $511M added.
- The largest Vertex Pharmaceuticals seller in Q3 2018 was Capital World Investors, an estimated $586M sold.
Based on aggregated 13F filings for Q3 2018.